enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Direct factor Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

   [4] [5] [6] They are commonly prescribed to treat and prevent blood clots in veins, prevent stroke and embolism in people with non-valvular atrial fibrillation (AF) who have other risk factors, and prevent blood clots after routine knee and hip replacement surgery. [2] [3] [7]

3. Apixaban - Wikipedia

   en.wikipedia.org/wiki/Apixaban

   Apixaban is recommended by the National Institute for Health and Clinical Excellence for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation and at least one of the following risk factors: prior stroke or transient ischemic attack, age 75 years or older, diabetes, or symptomatic heart failure.

4. Prasugrel - Wikipedia

   en.wikipedia.org/wiki/Prasugrel

   Prasugrel, sold under the brand names Effient and Efient, is a medication used to prevent formation of blood clots.It is a platelet inhibitor and an irreversible antagonist of P2Y 12 ADP receptors and is of the thienopyridine drug class.

5. Is Eliquis Covered by Medicare? - AOL

   www.aol.com/eliquis-covered-medicare-140000963.html

   Eliquis (apixaban) is covered by most Medicare prescription drug coverage plans. Eliquis is an anticoagulant used to lower the chance of stroke in people with atrial fibrillation (AFib), a common ...

6. ELIQUIS® (apixaban) Demonstrates Consistent Reductions in ...

   www.aol.com/news/2012-10-01-eliquis-apixaban...

   ELIQUIS ® (apixaban) Demonstrates Consistent Reductions in Stroke and Systemic Embolism, Major Bleeding and Mortality Compared to Warfarin in Patients with Nonvalvular Atrial Fibrillation at ...

7. U.S. FDA Approves ELIQUIS® (apixaban) to Reduce the ... - AOL

   www.aol.com/news/2013-01-02-us-fda-approves...

   U.S. FDA Approves ELIQUIS ® (apixaban) to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation ELIQUIS Demonstrated Superior Risk Reductions Versus ...